Researchers from the United States have now found that the immune recall induced by a two-dose primary series of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination after an initial natural infection highly improves the longevity of the antibodies as well as induces an enhanced breadth of protection across the SARS-CoV-2 variants.
Researchers demonstrated the inhalation of an ACE2 decoy receptor, sACE22.v2.4-IgG1, increases survival and ameliorates lung injury in K18-hACE2 transgenic mice.
A research team collaborating across the University of Texas Medical Branch-Galveston, Pfizer Vaccine Research, and BioNTech SE recently conducted a study on the neutralization capacity of the.
A new study captured an instance of SARS-CoV-2 superinfection in an individual, simultaneously infected by two SARS-CoV-2 variants, Alpha and Epsilon during the second COVID-19 wave in New York City in early 2021.